Home / Treatments / Antibiotics
Antibiotics denials: what the review data shows
Independent reviewers have decided 202 published cases where an insurer denied Antibiotics — and they overturned the insurer 41.6% of the time. A denial for Antibiotics is a starting position, not a final answer.
Published decisions
202
2001–2026
Overturned
41.6%
84 denials reversed
Conditions behind antibiotics denials
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Lyme Disease | 61 | 4.9% |
| Bacterial Infection | 24 | 54.2% |
| Irritable Bowel Syndrome | 9 | 77.8% |
| Irritable Bowel | 8 | 75% |
| Sinusitis | 6 | 50% |
| Infection | 3 | 100% |
| Abdominal Stomach Pain | 3 | 100% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 160 | 50% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 42 | 9.5% |
Typical time to a decision
18 days
Most land between 7 and 21 days
Handled as urgent
31.7%
Expedited when a delay would cause harm
Recent direction
Rising
60.9% → 81.3% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Physician 1: This patient is a 43-year-old female who underwent renal transplant in 1992 due to focal segmental glomerulosclerosis (FSGS). She is on now on dialysis and requires a second renal transplant. A live donor is available; however the patient is highly sensitized and had a positive crossmatch with the potential donor. The patient’s transplant specialist recommends desensitization with IVIG and Rituxan prior to transplant, and indicates that plasmapheresis may also be required. The provider’s request for authorization of the desensitization protocols was denied by the Health Plan citing the experimental nature of the therapies.The proposed therapies are considered to be the standard of care and are not investigational.
The enrollee is a 53-year-old female who has a 4.5-year history of chronic sinusitis with recurrent acute infection. Additionally she has problems with migraine headaches and has been diagnosed with fibromyalgia. An additional compounding factor in this patient’s care is her stated history of multiple antibiotic allergy. Initial treatment in November 2000 included oral antibiotics and nasal saline irrigation. A CT scan in December 2000 showed “near complete filling of the maxillary sinuses” with osteomeatal complex obstruction, minimal patchy disease of the ethmoids, clear sphenoids, and undeveloped frontal sinuses. After failure of initial therapy the patient underwent bilateral FESS as well as septoplasty. The surgeon notes the findings of “thick fungal” material at surgery.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Physician 1The patient is a 34-year-old female first diagnosed with Lyme disease in 2001. She subsequently received multiple courses of antibiotic with minimal long-term results. She had one six-month course of antibiotic with minimal change in her condition. She reports experiencing fatigue, paresthesia, arthralgias, fever, photophobia and headaches. These symptoms have persisted for several years. The patient feels the symptoms are increasing in severity. Physical exam findings include peripheral neuropathy with no effusions or erosion of large joints. Laboratory data include a positive IgG Western blot, normal brain MRI, and abnormal nerve conduction studies. No CSF analysis has been provided. A request has been made for continued intravenous antibiotic therapy.
Physician 1: The patient is a 65-year-old man who is said to have a history of Lyme disease. There is no evidence in the provided materials that the patient actually had this disease. The results of the definitive serological tests (Western Blots) included in the records are not conclusive. No other laboratory data of consequence is provided. There is a CD57 count that is slightly low and a non-specific SPECT brain scan performed in 2003; these are not diagnostic of Lyme disease.There is no mention in the submitted information of tick exposure or the characteristic rash seen in early Lyme disease. The medical records provided are from the patient’s primary care physician. The records note the patient is being treated with intravenous Rocephin and a quinolone antibiotic. He was given intravenous Rocephin for 10.5 months.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Antibioticswhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.